Grotesque conflicts of interest on NIH ivermectin non-recommendation

Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.

The National Institutes of Health provided a non-recommendation for the use of ivermectin in COVID-19, stating that there was:

“insufficient evidence … to recommend either for or against the use of ivermectin for the treatment of COVID-19.”

The process for reaching that non-recommendation, however, is opaque. The Panel members responsible for therapy recommendations are disclosed and also that:

“… working groups propose updates to the Guidelines based on the latest published research findings and evolving clinical information.”

However, NIH has gone to extreme efforts to avoid stating whether a vote was held to endorse the ivermectin non-recommendation. This includes fighting a Freedom of Information Act request in federal court. A deceptive non-vote would constitute an atrocity. NIH has also been secretive about the composition of the working group that proposed the ivermectin non-recommendation. The names of those individuals were redacted by the NIH from a document obtained through a Freedom of Information Act re...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee